• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Impact of the Covid-19 pandemic on haematology research trials at the Christie Hospital

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Saleem, Sana
    Day, Clare
    Armstrong, Emma-Frances
    Searle, Emma J
    Affiliation
    Haematology & Transplant and Lymphoma Research Departments, Christie Hospital, Manchester
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Covid-19 has spread across the globe causing a devastating number of deaths and impacting on every aspect of life as never before. The NHS Constitution recognises the important role of the NHS to “conduct and use of research to improve the current and future health and care of the population” [1]. The pandemic demonstrated the ability of the NHS to make meaningful contributions to key clinical research relating to the management of COVID-19 but placed unprecedented challenges on other areas of clinical research. The Christie Hospital is one of the largest dedicated cancer treatment centres in Europe. As well as providing expert cancer care, it is a tertiary research centre with an internationally recognised expertise in cancer research. We looked at the impact of COVID-19 haematooncology clinical research activity at The Christie. Clinical trial activity records were reviewed for the 6-month time periods before (Sept. – Feb. 2019-20), during (Mar. – Aug. 2020) and after (Sept. – Feb. 2020-21) the first UK lockdown. Effects on the opening of and recruitment to clinical trials were analysed. In addition, adaptions made to the delivery of clinical research, were considered. The lockdown brought about a dramatic decline in patient recruitment, from 7 to 2 patients/month. This reflects a decision to almost totally halt recruitment to allow research staff to be redeployed and protocols to be implemented to minimise the risk to research patients from COVID-19 infection whilst on the hospital site. Following this, a cautious recovery period began in which clinical trial recruitment resumed, whilst maintaining COVID-19 safety measures, allowing recruitment recovery to near pre-lockdown levels; 6 patients/month. A delayed effect on new trial opening was observed. In the prelockdown 6-month period, 9 new trials were opened, with 8 opened during lockdown. This fell to 6 trials in the following 6-months. The delayed effect was likely due to the length of the setup process, with much work already having occurred before the lockdown allowing ongoing new trial opening. However, new trial set up has been slow to recover, impacted by ongoing pressures on service departments (e.g., radiology) preventing timely reviews as part of the set-up process. Documented deviations from trial protocol were agreed with sponsors and seen as necessary to conduct clinical haemato-oncology research safely within the setting of a pandemic. Examples documented include switching from face-to-face to remote consultations and omitting or relocating some trial related investigations. A potential impact on data quality was accepted and deviations were recorded to allow review of this impact at a later date. Other key changes included the expediting of a move to allow remote, anonymised, supervised, electronic record access for trial monitoring visits, and specialised courier delivery of trial medication, where appropriate. As a dedicated tertiary cancer hospital, there was organisational motivation to try to safely resume clinical research activity following the first lockdown. The consequences of halting clinical haemato-oncology research on future developments within the field is difficult to quantify but potentially serious. It is essential that clinical cancer research learns to adapt to the ‘new normal’ in the COVID era. [1] Department of Health and Social Care, NHS Constitution for England (2012), accessed 1/2/21
    Citation
    Saleem S, Day C, Armstrong E, Searle E. Impact of the Covid-19 pandemic on haematology research trials at the Christie Hospital. British Journal of Haematology. 2021;193:87-8.
    Journal
    British Journal of Haematology
    URI
    http://hdl.handle.net/10541/624061
    Type
    Meetings and Proceedings
    Language
    en
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.